Literature DB >> 15388618

Taking account of future technology in cost effectiveness analysis.

Joshua A Salomon1, Milton C Weinstein, Sue J Goldie.   

Abstract

Mesh：

Year:  2004        PMID： 15388618      PMCID： PMC518904          DOI： 10.1136/bmj.329.7468.733

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  15 in total

1.  Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis.

Authors:  J B Wong; R S Koff
Journal:  Ann Intern Med       Date:  2000-11-07       Impact factor: 25.391

Review 2.  An introduction to Markov modelling for economic evaluation.

Authors:  A Briggs; M Sculpher
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

3.  Natural history of hepatitis C.

Authors:  L B Seeff
Journal:  Am J Med       Date:  1999-12-27       Impact factor: 4.965

4.  Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal.

Authors:  Christopher Evans; Manouche Tavakoli; Bruce Crawford
Journal:  Health Care Manag Sci       Date:  2004-02

5.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

6.  Foundations of cost-effectiveness analysis for health and medical practices.

Authors:  M C Weinstein; W B Stason
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

7.  Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

Authors:  W G Bennett; Y Inoue; J R Beck; J B Wong; S G Pauker; G L Davis
Journal:  Ann Intern Med       Date:  1997-11-15       Impact factor: 25.391

Review 8.  Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome.

Authors:  H J Alter; L B Seeff
Journal:  Semin Liver Dis       Date:  2000       Impact factor: 6.115

9.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

10.  Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group.

Authors: 
Journal:  Hepatology       Date:  1994-07       Impact factor: 17.425
View more
  9 in total

1.  Population- versus cohort-based modelling approaches.

Authors:  Olivier Ethgen; Baudouin Standaert
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

2.  Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis.

Authors:  Martin Hoyle
Journal:  Pharmacoeconomics       Date:  2011-01       Impact factor: 4.981

3.  Comment on: "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy".

Authors:  Afschin Gandjour
Journal:  Pharmacoeconomics       Date:  2015-09       Impact factor: 4.981

4.  Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.

Authors:  Katia Noyes; Andrew W Dick; Robert G Holloway
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Optimal assignment of treatments to health states using a Markov decision model: an introduction to basic concepts.

Authors:  Mohan V Bala; Josephine A Mauskopf
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  Modelling downstream effects in the presence of technological change.

Authors:  Duncan Mortimer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

7.  Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.

Authors:  Annemieke De Ridder; Diana De Graeve
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

8.  Modeling the impact of genetic screening technologies on healthcare: theoretical model for asthma in children.

Authors:  Emma Gutiérrez de Mesa; Ignacio Hidalgo; Panayotis Christidis; Juan Carlos Ciscar; Eva Vegas; Dolores Ibarreta
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

9.  Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment.

Authors:  Shan Liu; Margaret L Brandeau; Jeremy D Goldhaber-Fiebert
Journal:  Health Care Manag Sci       Date:  2015-07-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.